Uterine endometrial stromal sarcoma revealed after treatment of uterine fibroid with ulipristal acetate: a case report

Background: High-grade endometrial stromal sarcomas (ESS) are very rare uterine tumors which grow from endometrial stroma and include less than 2% of uterine malignant tumors. Preoperatively it is often difficult to diagnose these tumors due to its image of benign tumors. The authors present a first in the literature, case of a 47-year-old patient with high-grade ESS diagnosed in histopathological examination after treatment with ulipristal acetate. Case Report: Patient was operated with recognition of leiomyoma and was after three months treatment of uterine fibroid with ulipristal acetate. The histopathological examination revealed a high grade ESS and endometrium had the features of hyperplasia without atypia. One month after first operation, patient was reoperated to expand surgery according to oncologic protocol and remove cervix, adnexa, pelvic and para-aortic lymph nodes, and explore pelvic and abdominal cavity. All these organs were without neoplastic features. Patient was qualified to postoperative radiation and chemotherapy. Conclusions: In ESS hormone receptors are usually positive and activity of progesterone receptor modulators can influence on course of disease. This case report suggests that the patients qualification for treatment should be preceded by careful and precise clinical examination with precise ultrasound assessment of myoma, flow in uterine arteries, and pattern of flow inside fibroid tumor.

Endometrial stromal sarcoma; Ulipristal acetate; Case report.

[1] Bacalba N., Balescu I.: “Atypical paracaval recurrence of uterine endometrial stromal sarcoma: a case report”. Anticancer Res., 2015, 35, 3405.

[2] Ali R.H., Rouzbahman M.:.”Endometrial stromal tumours revisited: an update based on the 2014 WHO classification”. J. Clin. Pathol., 2015, 68, 325.

[3] Jain R., Batra S., Ahmad A., Elahi A.A., Gupta M., Saith P.: “Low grade endometrial stromal sarcoma: a case report”. Iran J. Med. Sci., 2015, 40, 81.

[4] Lange S.S., Novetsky A.P., Powell M.A.: “Recent advances in the treatment of sarcomas in gynecology”. Discov. Med., 2014, 18, 133.

[5] Hata K., Makihara K., Hata T., Takahashi K., Kitao M.: “Transvaginal color Doppler imaging for hemodynamic assessment of reproductive tract tumors”. Int. J. Gynaecol. Obstet., 1991, 36, 301.

[6] West C.P.: “Hysterectomy and myomectomy by laparotomy”. Baillieres Clin. Obstet. Gynaecol., 1998, 12, 317.

[7] Sladkevicius P., Valentin L., Marsal K.: “Transvaginal Doppler examination of uteri with myomas”. J. Clin. Ultrasound, 1996, 24, 135.

[8] Walocha J.A., Litwin J.A., Miodonski A.J.: “Vascular system of intramural leiomyomata revealed by corrosion casting and scanning electron microscopy”. Hum. Reprod., 2003, 18, 1088.

[9] Exacoustos C., Romanini M.E., Amadio A., Amoroso C., Szabolcs B., Zupi E., et al.: “Can gray-scale and color Doppler sonography differentiate between uterine leiomyosarcoma and leiomyoma?” J. Clin. Ultrasound, 2007, 35, 449.

[10] Donnez J., Hudecek R., Donnez O., Matule D., Arhendt H.J., Zatik J., et al.: “Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids”. Fertil. Steril., 2015, 103, 519.

[11]Donnez J., Vázquez F., Tomaszewski J., Nouri K., Bouchard P., Fauser B.C., et al.: “PEARL III and PEARL III Extension Study Group. Long-term treatment of uterine fibroids with ulipristal acetate”. Fertil. Steril., 2014, 10, 1565.

[12] Donnez J., Tomaszewski J., Vázquez F., Bouchard P., Lemieszczuk B., Baró F., et al.: “PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids”. N. Engl. J. Med., 2012, 366, 421.

[13] Donnez J., Tatarchuk T.F., Bouchard P., Puscasiu L., Zakharenko N.F., Ivanova T., et al.: “PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery”. N. Engl. J. Med., 2012, 366, 409.

[14] Williams A.R., Bergeron C., Barlow D.H., Ferenczy A.: “Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate”. Int. J. Gynecol. Pathol., 2012, 31, 556.

[15] Mutter G.L., Bergeron C., Deligdisch L., Ferenczy A., Glant M., Merino M., et al.: “The spectrum of endometrial pathology induced by progesterone receptor modulators”. Mod Pathol., 2008, 21, 591.

[16] Biglia N., Carinelli S., Maiorana A., D’Alonzo M., Lo Monte G., Marci R.: “Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids”. Drug Des. Devel. Ther., 2014, 8, 285.

[17] Choo K.J., Lee H.J., Lee T.S., Kim J.H., Koh S.B., Choi Y.S.: “Intrapelvic dissemination of early low-grade endometrioid stromal sarcoma due to electronic morcellation”. Obstet. Gynecol. Sci., 2015, 58, 414.

[18] Beckmann M.W., Juhasz-Böss I., Denschlag D., Gaß P., Dimpfl T., Harter P., et al.: “Surgical Methods for the Treatment of Uterine Fibroids - Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGG”. Geburtshilfe Frauenheilkd., 2015, 75, 148.

[19] Pujani M., Jairajpuri Z.S., Rana S., Jetley S., Hassan M.J., Jain R.: “Cellular leiomyoma versus endometrial stromal tumor: A pathologists’ dilemma”. J. Midlife Health, 2015, 6, 31.

[20] Chu M.C., Mor G., Lim C., Zheng W., Parkash V., Schwartz P.E.: “Low-grade endometrial stromal sarcoma: hormonal aspects”. Gynecol. Oncol., 2003, 90, 170.

[21] Chan J.K., Kawar N.M., Shin J.Y., Osann K., Chen L.M., Powell C.B., Kapp D.S.: “Endometrial stromal sarcoma: a population-based analysis”. Br. J. Cancer, 2008, 99, 1210.

[22] Guiqiu L., Chuanshan Z., Zhe M., Qin Z., Bingbing L.: “Endometrial stromal sarcoma with endometrioid adenocarcinoma of the uterus: a case report”. Int. J. Clin. Exp. Pathol., 2015, 8, 5242.